Skip to main content

Table 3 Overview of the unadjusted mean changes from baseline to the last follow-up visit at month 6 between eyes with central retinal vein occlusion related macular edema (CVRO-ME) and those with macular edema secondary to branch retinal vein occlusion (BRVO-ME), and between treatment-naïve eyes and those previously treated

From: Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant

Variables Overall (n = 57)
Mean difference (95% CI) from baseline Pb
BCVA 2.0 (−5.7 to 9.7) 0.6114
CRT, μm − 240.7 (− 318.4 to − 162.9) < 0.0001
CST, μm 1.7 (−17.8 to 21.3) 0.8594
NMCST500, μm 12.6 (−5.2 to 30.5) 0.1615
NMCST1500, μm 1.8 (−18.5 to 22.2) 0.8581
TMCST500, μm 7.4 (−14.4 to 29.3) 0.4992
TMCST1500, μm 12.6 (−8.0 to 33.2) 0.2257
Cyst volume, μm3 −195.8 (− 255.5 to − 136.1) < 0.0001
SRF, μm −114.3 (− 159.8 to −68.7) < 0.0001
  CRVO (n = 15) BRVO (n = 42) Difference between treatment groupsc
Mean difference (95% CI) from baseline pa Mean difference (95% CI) from baseline pa Median differenced(95% CI) Pb
BCVA −9.5 (−25.5 to 6.5) 0.2248 6.1 (− 2.8 to 14.9) 0.1739 16.0 (0.0 to 35.0) 0.0798
CRT, μm − 194.2 (− 340.7 to 47.7) 0.0130 −257.3 (−351.9 to −162.6) < 0.0001 − 45.5 (− 227.0 to 127.0) 0.6311
CST, μm 15.0 (−30.2 to 60.2) 0.4883 −3.0 (− 25.2 to 19.2) 0.7859 −16.0 (−68.0 to 30.0) 0.4967
NMCST500, μm 25.9 (−10.6 to 62.5) 0.1502 7.9 (−13.3 to 29.0) 0.4556 −11.0 (−54.0 to 30.0) 0.6768
NMCST1500, μm 13.5 (−35.2 to 62.1) 0.5619 −2.3 (− 25.1 to 20.4) 0.8370 −6.5 (− 61.0 to 39.0) 0.7788
TMCST500, μm 7.7 (−56.2 to 71.7) 0.7990 7.3 (−14.1 to 28.7) 0.4943 −11.5 (− 55.0 to 31.0) 0.5259
TMCST1500, μm 19.1 (−38.2 to 76.4) 0.4856 10.3 (−10.8 to 31.3) 0.3302 −11.0 (−60.0 to 48.0) 0.5992
Cyst volume, μm3 − 140.1 (−267.5 to −12.7) 0.0335 − 216.2 (− 285.5 to − 146.8) < 0.0001 −68.0 (− 207.0 to 85.0) 0.3323
SRF, μm −58.3 (− 116.6 to 0.0) 0.0500 −139.9 (−200.5 to −79.4) 0.0001 −3.0 (− 60.0 to − 52.0) 0.6015
  Naïve (n = 31) Previously treated (n = 26) Difference between treatment groupsc
Mean difference (95% CI) from baseline pa Mean difference (95% CI) from baseline pa Median difference (95% CI)d Pb
BCVA 11.0 (0.4 to 21.6) 0.0428 −8.8 (−19.2 to 1.6) 0.0928 −18.0 (−35.0 to −4.0) 0.0129
CRT, μm − 269.8 (−399.4 to −140.3) 0.0002 −205.9 (−286.9 to − 124.9) < 0.0001 41.5 (−120.0 to 197.0) 0.6251
CST 1.4 (−23.2 to 25.9) 0.9110 2.2 (−31.1 to 35.5) 0.8932 4.0 (−41.0 to 46.0) 0.8413
NMCST500 12.9 (−8.8 to 34.5) 0.2342 12.3 (−18.8 to 43.5) 0.4218 −3.0 (−40.0 to 33.0) 0.8039
NMCST1500 4.0 (−21.5 to 29.6) 0.7494 −0.8 (−35.4 to 33.8) 0.9620 −9.0 (−52.0 to 32.0) 0.6307
TMCST500 7.6 (−23.0 to 38.3) 0.6137 7.2 (−26.2 to 40.6) 0.6630 0.0 (− 36.0 to 43.0) 0.9872
TMCST1500 21.3 (−5.2 to 47.8) 0.1105 2.2 (−31.7 to 36.1) 0.8951 −4.0 (−47.0 to 39.0) 0.8538
Cyst volume, μm3 −218.8 (− 304.5 to − 133.2) < 0.0001 − 169.2 (−256.9 to −81.5) 0.0005 70.5 (−80.0 to 181.0) 0.3653
SRF, μm − 128.9 (−202.3 to − 55.5) 0.0015 −92.3 (− 133.9 to − 50.7) 0.0004 0.0 (−64.0 to 48.0) 0.8969
  1. CRVO Central retinal vein occlusion, BRVO Branch retinal vein occlusion, CI Confidence interval, BCVA Best corrected visual acuity, CRT Central retinal thickness, CST Central subfoveal thickness, NRT Nasal retinal thickness, 500 ring of 500 μm, 1500 Ring of 1500 μm, TRT Temporal retinal thickness, SRF Subretinal fluid
  2. aTwo-way analysis of variance (ANOVA) test
  3. bMann-Whitney U test
  4. cFirst column versus (VS) the second one
  5. dHodges-Lehmann median difference (95% Confidence interval)